A 24-week, observational, multicentre study to evaluate efficacy and tolerability of telaprevir (TVR)-based triple therapy in Spanish genotype 1 hepatitis C (HCV)–HIV co-infected patients with with compensated liver cirrhosis.

Trial Profile

A 24-week, observational, multicentre study to evaluate efficacy and tolerability of telaprevir (TVR)-based triple therapy in Spanish genotype 1 hepatitis C (HCV)–HIV co-infected patients with with compensated liver cirrhosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2015

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Dec 2015 New trial record
    • 31 Jan 2014 Interim results published in the Antiviral Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top